Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 2/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20677174 | 0.88 | KIF11 (0.36) | — | |
| Trifluoroacetic Acid SCHEMBL18261734 | 0.75 | AKT1 (0.38) | TACR1TACR3TERTAKT1 | |
| SCHEMBL17841877 | 0.71 | TERT (0.40) | TERTAKT1 | |
| SCHEMBL30269173 | 0.71 | TERT (0.40) | TERTAKT1 | |
| SCHEMBL22973514 | 0.71 | AKT1 (0.42) | AKT1 | |
| SCHEMBL28646996 | 0.69 | TSHR (0.35) | TERTAKT1 | |
| SCHEMBL22382527 | 0.68 | TACR1 (0.32) | TACR1TACR3 | |
| Trifluoroacetic Acid SCHEMBL27959221 | 0.66 | ALDH1A1 (0.35) | AKT1 | |
| SCHEMBL16095877 | 0.64 | DRD2 (0.36) | AKT1 | |
| SCHEMBL460703 | 0.64 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| EP-3558387-A1 | SPECIFIC ANTIBODY DRUG CONJUGATES (ADCS) HAVING KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | TACR1 3405/4885TACR3 4053/4885TERT 4710/4885 |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | KIF23, KIF5B, KIF2C | TACR1 3681/4885TACR3 2992/4885TERT 4876/4885 |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | TACR1 3681/4885TACR3 2992/4885TERT 4876/4885 |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | TACR1 3405/4885TACR3 4053/4885TERT 4710/4885 |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | TACR1 3405/4885TACR3 4053/4885TERT 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.